Determination of Tigecycline in Plasma and Bronchoalveolar Lavage Fluid by UPLC–MS/MS and Its Application to a Pharmacokinetic Study in Critically Ill Patients
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70055 ↗At a glance
Journal article in Biomedical Chromatography, 2025. Written by Nan Guo and 8 co-authors. Institution: Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. Major MEDLINE topics: Tigecycline, Tandem Mass Spectrometry, Bronchoalveolar Lavage Fluid, Anti-Bacterial Agents. Cited 3 times so far (Crossref); 23 references. Funded by: Medical and Health Science and Technology Development Project of Shandong Province, Special Foundation for Clinical Pharmacy Research of Shandong Medical Association, Natural Science Foundation of Shandong Province.
Abstract (original language)
Tigecycline has been widely used for treating infections caused by multidrug resistant bacteria, but the dosage and intrapulmonary distribution were still controversial. In this study, a UPLC–MS/MS method was established and fully validated to quantify tigecycline in human plasma and BALF. A simple and rapid protein precipitation was used to extract the analytes from plasma and BALF samples. Then, tigecycline and IS were separated on a SHIMADZU AQ‐C18 column and detected using electrospray ionization positive ion mode using the transitions of m / z 586.3 → 513.2 m / z for TGC and 458.0 → 441.0 m / z for minocycline (IS). The linearity of the calibration was in the range of 20–2000 ng/mL in plasma and BALF. The validated method was successfully applied to investigate pharmacokinetic characteristics of tigecycline in critically ill patients. The results suggested that after intravenous administration of 100‐mg q12h tigecycline, the AUC 0–12 was 3663.02 ± 2075.84 ng × h/mL and C ss,av was 305.25 ± 172.99 ng/mL; the average plasma concentration/ELF concentration ratio was 3.66. Significant individual differences and highly variable pharmacokinetic properties were observed, indicating that adjustment of dosing regimens according to therapeutic drug monitoring is effective and efficient to guarantee the drug efficacy and safety especially for critically ill patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
- Department of Graduate, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- Department of Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
- Department of Gynecology, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Funding
- Medical and Health Science and Technology Development Project of Shandong Province
- Special Foundation for Clinical Pharmacy Research of Shandong Medical Association
- Natural Science Foundation of Shandong Province
Cite
APA
Guo, N., Hu, S., Zhang, Y., Zhang, W., Li, D., Tang, Y., Tai, Z., Guo, X., & Leng, B. (2025). Determination of Tigecycline in Plasma and Bronchoalveolar Lavage Fluid by UPLC–MS/MS and Its Application to a Pharmacokinetic Study in Critically Ill Patients. Biomedical Chromatography. https://doi.org/10.1002/bmc.70055
Vancouver
Guo N, Hu S, Zhang Y, Zhang W, Li D, Tang Y, et al. Determination of Tigecycline in Plasma and Bronchoalveolar Lavage Fluid by UPLC–MS/MS and Its Application to a Pharmacokinetic Study in Critically Ill Patients. Biomedical Chromatography. 2025. doi:10.1002/bmc.70055
BibTeX
@article{Guo2025,
author = {Guo, Nan and Hu, Sheng and Zhang, Yahui and Zhang, Wen and Li, Dejun and Tang, Yue and Tai, Zijian and Guo, Xin and Leng, Bing},
title = {Determination of Tigecycline in Plasma and Bronchoalveolar Lavage Fluid by UPLC–MS/MS and Its Application to a Pharmacokinetic Study in Critically Ill Patients},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70055}
}
EUVIMED